Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

CDMO, uBriGene, Expands to the US Market with Major Acquisition

Banner
Kadeja Johnson
19 May 2023
SHARE NOW
CAR-X
Cell Therapy
Clinical Trials
Collaborations, Mergers & Acquisitions
Gene Therapy
GMP
Partnering
Cell and Gene Therapy, UBriGene, is expanding into the US market with a state-of-the-art GMP manufacturing facility acquired from Mustang Bio, Inc., a NASDAQ-listed company. The site has successfully manufactured CAR-T products to support clinical trials, as well as performing analytical and process development work supporting the products.

Headquartered in Vancouver, Canada, uBriGene has established global recognition with two GMP manufacturing facilities in China. uBriGene will take over the clinical manufacturing of Mustang Bio’s MB-106, a CAR-T cell therapy treatment for a range of hematological malignancies, including Waldenstrom macroglobulinemia, a rare malignant disorder of the bone marrow and lymphatic tissues.

The newly acquired 27,000-square-foot manufacturing site in Worcester, Boston, Massachusetts, has a suite of clinical facilities for the production of cell and gene therapies and will provide contract analytical services. The move will foresee high-value job and growth opportunities in the greater Boston area, increasing its total global employee number to over 500 employees.

The site has fully integrated technology transfer, quality control testing, manufacturing development, warehousing and cGMP storage capabilities, designed for multiproduct cGMP manufacturing of multiple gene-modified cell types.

“This acquisition is important to uBriGene’s commitment to support the development, clinical, and commercial supply of cell and gene therapies to meet rapidly growing demand,” highlighted Alex Chen, President of uBriGene. “We hope to work together with the University of Massachusetts Medical School to continue to grow the advanced therapy manufacturing ecosystem in the Worcester region.”

How are you enjoying this news article? Let us know your thoughts, here >>

 

Chen further explained how the partnership between uBriGene and Mustang Bio is beneficial:

“This partnership enables us to expand rapidly to create a North American presence and offer the same high-quality cell and gene therapy development and manufacturing capabilities for the U.S. that we currently provide in Asia, including to support Mustang Bio’s lead clinical-stage CAR-T program.”

Mustang Bio’s CEO also commented on the partnership detailing the potential to advance Mustang Bio’s novel leading cell therapy progression in the US:

“Mustang is excited to be partnering with uBriGene to advance our novel leading cell therapy programs and leverage their global manufacturing and development expertise to progress our advanced cellular therapies through clinical trials in the United States.”

Source: uBriGene Press Release 


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.

More like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023

Discover more like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

Broken String Bioscience Closes $15M Series A Funding Round

FDA Delays the Review of Iovance’s BLA Treatment of Advanced Melanoma

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022